Skip to main content
Oryzon Genomics S.A. logo

Oryzon Genomics S.A. — Investor Relations & Filings

Ticker · ORY ISIN · ES0167733015 LEI · 95980063R15RDF29DK13 MC Manufacturing
Open in API
Filings indexed 142 across all filing types
Latest filing 2021-05-07 Interim / Quarterly Rep…
Country ES Spain
Listing MC ORY

About Oryzon Genomics S.A.

https://www.oryzon.com/en

Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.

Recent filings

Filing Released Lang Actions
La Sociedad remite información sobre los resultados del primer trimestre de 2021
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly financial report for Oryzon Genomics, S.A. covering the first quarter of 2021. It includes a detailed 'Nota de Resultados' (Results Note), business evolution updates, and a formal 'Cuenta de Resultados' (Income Statement) comparing Q1 2021 to Q1 2020. It is not merely an announcement of a report, as it contains substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-07 Spanish
ORYZON presenta datos clínicos de 12 meses de sus ensayos clínicos de Fase IIa en Alzheimer con vafidemstat, ETHERAL y REIMAGINE-AD, en la Conferencia virtual AD/PD-2021.
Regulatory Filings Classification · 99% confidence The document is a formal communication from ORYZON GENOMICS, S.A. to the market, starting with a reference to Spanish securities law (artículo 227 del texto refundido de la Ley del Mercado de Valores) and labeled as 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The core content announces the presentation of 12-month clinical trial data (ETHERAL and REIMAGINE-AD) at the AD/PD-2021 conference and includes a summary press release detailing the results. Crucially, it states: 'Un resumen de estos resultados se incluye en la nota de prensa que se adjunta como anexo y que será distribuida en el día de hoy.' This structure—a brief regulatory notification announcing the release of detailed information (a press release/data summary) that is attached or linked—strongly suggests this is an announcement about the release of information rather than the full, comprehensive report itself (like an ER or IR). Since it is a general regulatory announcement about data presentation and includes links to the actual posters/summaries, it fits best under the general regulatory announcement category, 'Regulatory Filings' (RNS), as it is not a specific financial report (10-K, IR, ER) or a specific corporate action announcement (DIV, CAP, DIRS). Given the document length is substantial (12,685 chars), it is more than just a placeholder, but its primary function is to disseminate news about data presented at a conference, which often falls under RNS if no other specific code applies.
2021-03-09 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 99% confidence The document is titled "STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM". This form is used to report insider trading or transactions by directors/managers. The content details a transaction (Venta/Sale) by a director ('Consejera dominical') of ORYZON GENOMICS, S.A. This specific type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of 'Director's Dealing'.
2021-02-27 Spanish
Oryzon remite nota de prensa sobre resultados del ejercicio 2020
Earnings Release Classification · 98% confidence The document is explicitly titled as a communication regarding results for the 'CUARTO TRIMESTRE DE 2020' (Fourth Quarter of 2020) and includes detailed financial tables (Cuenta de Resultados and Balance Sheet) for that period, comparing them to 2019. It is described as a 'NOTA DE RESULTADOS' (Results Note) and is accompanied by a press release header ('PRESS RELEASE 2021'). This content structure—detailed financial figures, operational updates for a specific fiscal period, and a formal announcement—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it covers the full fourth quarter and includes comprehensive financial statements (P&L and Balance Sheet), it goes beyond the 'key highlights only' scope of a typical ER and aligns more closely with a comprehensive quarterly report. However, in many regulatory contexts, the initial announcement summarizing the period's results, often released alongside or immediately preceding the full filing, is classified as an Earnings Release (ER). Given the context of a 'nota de prensa' (press release) announcing the Q4 2020 results, ER is the most appropriate classification for this initial disclosure, even though it contains substantial detail. It is not a 10-K (Annual Report) as it is quarterly, nor is it a simple RPA as it contains the results themselves, not just an announcement of an attached report. Q4 2020
2021-02-22 Spanish
Corporate Governance Report - Oryzon Genomics S.A.
Remuneration Information Classification · 99% confidence The document text is titled 'DATOS IDENTIFICATIVOS DEL EMISOR' and contains extensive sections detailing 'POLÍTICA DE REMUNERACIONES DE LA SOCIEDAD PARA EL EJERCICIO EN CURSO' (Remuneration Policy for the Current Fiscal Year). It discusses principles, fixed and variable components, mix retributivo, risk mitigation measures related to compensation, and specific details about the remuneration of directors and executives for the fiscal year ending 31/12/2020. This content directly corresponds to the disclosure requirements for executive and director compensation, which aligns with the definition of Remuneration Information (DEF 14A in US context, or similar governance/proxy disclosure regarding pay). Although the document is in Spanish, the subject matter is clearly remuneration policy disclosure.
2021-02-22 Spanish
Audit Report / Information 2020
Audit Report / Information Classification · 99% confidence The document text explicitly contains the header "INFORME DE AUDITORÍA DE CUENTAS ANUALES EMITIDO POR UN AUDITOR INDEPENDIENTE" (Audit Report of Annual Accounts issued by an Independent Auditor) and discusses the audit opinion, key audit matters (like capitalization of development expenses), and responsibilities of the auditor regarding the annual accounts for Oryzon Genomics, S.A. for the year ended December 31, 2020. This content directly corresponds to the definition of an Audit Report/Information (AR), which covers standalone audit reports, even though it relates to the annual accounts. FY 2020
2021-02-22 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.